Chronic Myelogenous Leukemia - Adult (Greater than or equal to 18 years old)

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson’s specific patient population, MD Anderson’s services and structure, and MD Anderson’s clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

Note: Consider clinical trials as treatment options for eligible patients.

**INITIAL EVALUATION**

- CML Chronic Phase
  - Early (diagnosis less than 12 months); include Ph-negative BCR/ABL-positive CML; less than 1 month

- CML Accelerated Phase
  - Untreated Imatinib Failures
  - Imatinib failures with T315I mutation - any stage

- CML Blastic Phase
  - Unstated

**TREATMENT**

- No response or relapse
  - 1st or 2nd generation Tyrosine Kinase Inhibitors
  - Or Clinical trials

- Minimal Residual Disease
  - Other Clinical Trials

- Surveillance as per protocol
  - Alternate TKI
  - Stem Cell Transplant
  - Or Clinical trials

**SURVEILLANCE**

- Surveillance

Note: Leukemia Patients should be referred and treated at a Comprehensive Cancer Center

TKI = Tyrosine Kinase Inhibitors

1. Leukemia Newsletter www address: http://www.mdanderson.org/leukemia (Available programs-treatment priorities)
2. If T315I, consider Ponatinib
3. After failure of more than one TKI

Department of Clinical Effectiveness V3
Approved by The Executive Committee of the Medical Staff 07/26/2016
SUGGESTED READINGS


Note: Consider clinical trials as treatment options for eligible patients.

Note: Leukemia Patients should be referred and treated at a Comprehensive Cancer Center.
Chronic Myelogenous Leukemia - Adult (Greater than or equal to 18 years old)

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson’s specific patient population; MD Anderson’s services and structure; and MD Anderson’s clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

Note: Consider clinical trials as treatment options for eligible patients.

Note: Leukemia Patients should be referred and treated at a Comprehensive Cancer Center

DEVELOPMENT CREDITS

This practice guideline is based on majority expert opinion of the Leukemia Center Faculty at the University of Texas, MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following medical oncologists.

Yesid Alvarado, MD
Michael Andrereff, MD
Kapil Bhalla, MD
Christopher Benton, MD
Gautam Borthakur, MD
Prithviraj Bose, MD
Jan Burger, MD
Jorge Cortes, MD†
Naval Daver, MD
Courtney DiNardo, MD
Zeev Estrov, MD
Alessandra Ferrajoli, MD†
Emil Freireich, MD
Guillermo Garcia-Manero, MD
Elias Jabbour, MD
Kiran Naqvi, MD
Jain Nitin, MBBS
Hagop M. Kantarjian, MD†
Tapan Kadia, MD
Michael Keating, MD
Marina Konopleva, MD
Steven Kornblau, MD
Maro Ohanian, DO
Naveen Pemmaraju, MD
Farhad Ravandi-Kashani, MD
Mary Beth Rios, RN†
Michael Ryting, MD
Koichi Takahashi, MD
Philip Thompson, MBBS
Srdan Verstovsek, MD
William Wierda, MD

†Core Development Team